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Backgrounds: To investigate the feasibility and efﬁcacy of concurrent 
hypofractionated chemo-radiotherapy using concomitant boost to gross 
tumor volume for patients with stage III non-small cell lung cancer 
(NSCLC). The hypothesis is that the shortened treatment time by hypo-
fractionated radiotherapy regimen would prevent accelerated repopula-
tion, and enhance the biological effects on cancer cells.
Methods: Forty-nine eligible patients with pathologically conﬁrmed 
Stage III NSCLC were enrolled between December of 2003 and August 
of 2005. Eighteen patients had stage IIIA and 31 patients had stage 
IIIB disease. Daily fractions of 2.4 Gy and 1.8 Gy were delivered to 
GTV and CTV to a total dose of 60 Gy and 45 Gy in 25 fractions over 
5 weeks, respectively, by using 3D-conformal radiotherapy techniques. 
All patients received concurrent weekly chemotherapy consisted of 
Paclitaxel (50 mg/m2 iv over 1 hour, days 1, 8, 15, 22, 29, 36) and Car-
boplatin (AUC=2, iv over 30 minutes, days 1, 8, 15, 22, 29, 36).
Results: With median follow-up periods of 21 (range, 16-38) months, 
median survival was 29 (range, 0.2-32) months. One and two year 
overall (OS), progression free (PFS), local progression free (LPFS), 
and distant metastases free survival (DMFS) rates were 82% and 65%, 
61% and 41%, 73% and 56%, and 85% and 72%, respectively. The 
compliance of radiotherapy was 90% (44/49 patients), and 88% (43/49) 
patients completed planned 5 cycles of chemotherapy. The response 
rate was 100% with 44% of near complete response and 56% of partial 
response. Two patients with T4 lesion (one with involvement of left 
atrium and the other with left pulmonary artery involvement) died of 
bleeding and hemoptysis during treatment (Grade 5). Acute esophagitis 
was the most common acute toxicity with twenty nine patients (59%) 
developing ≥ Grade 2 esophagitis. Five (10%) developed grade 3 he-
matologic tocicities, mostly neutropenia. Six (12%) patients developed 
late esophageal toxicity ≥ grade 3 and four (8%) had late pulmonary 
toxicities ≥ grade 3.
Conclusions: Our preliminary results are encouraging with higher 
OS and LPFS when compared to historical control. A careful patient 
selection is warranted since two patients with T4 with major vascular 
involvement died of tumor bleeding presumably due to rapid tumor 
regression at the site of major vessel involvement by accelerated radio-
therapy regimen using concomitant GTV boost. Other acute and late 
toxicities appear to be acceptable. A longer follow-up is needed.
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What effects do anatomic changes during treatment have on 
target and normal tissue dosimetry parameters of lung cancer 
radiotherapy? A multiple 4DCT analysis
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Background: In radiation therapy for locally advanced lung cancers, 
changes of tumor anatomy, mobility of tumor by respiration, and other 
uncertainties during the course of therapy may introduce signiﬁcant 
deviation of dose distributions from those planned initially before the 
start of therapy. Respiratory-correlated 4DCT imaging taken in a serial 
fashion during the therapy course could provide important spatio-tem-
poral information of tumors and anatomical structures. The purpose of 
this study is to understand such anatomical changes and their impact on 
the dose distributions for radiotherapy.
Methods: 4DCT imaging was repeated during every week of radia-
tion therapy using either 3D conformal or IMRT technique for a small 
cohort of non-small-cell lung cancer patients. Data from the weekly 
4DCT datasets were analyzed with respect to anatomical changes and 
tumor motion. Original treatment plans were reproduced onto weekly 
datasets using updated target and other anatomical structures, as well 
as isocenter geometry for a particular week. Dose distributions of all 
weekly plans were recalculated. Dosimetric changes to the PTV, ITV, 
and relevant normal structures relative to original treatment plans were 
analyzed. 
Results: For 5 patients who completed the study, weekly 4DCT images 
were acquired for 6 successive weeks during the course of therapy. The 
overall average (range) change in the percentage of volume of PTV 
and ITV covered by the 95% isodose (V95) between initial and during 
treatment was -4.0% (-15.3% to 2.1%) and -0.9% (-2.8% to 0.0%), 
respectively. The overall average change (range) in the dose to 95% 
of the PTV and ITV (D95) between initial and during treatment was 
-4.5Gy (-16.4Gy to 4.0Gy) and -0.5Gy (-2.4Gy to 1.2Gy), respectively. 
Initial normal tissues volumes were comparable to the weekly datasets. 
The overall mean variation (range) between initial vs. mean weekly 
percent total lung volume exceeding 20Gy (V20), mean total lung 
doses, and cord maximum doses were -0.6% (-3.5% to 2.4%), -0.4Gy 
(-2.6Gy to 1.7Gy) and 6.5Gy (-1.4Gy to 15.6Gy), respectively.
Dosimetric comparison of radiation doses to target and significant normal 
tissue volumes at planning and during the course treatment as derived from 
serial 4DCT imaging.
